Search the Newsreel

Steelcast stock trades up to 305.00 as Steelcase promotes home office design themes

Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval

Despite a significant 7x return over three years and the FDA approval of REVTORPYK, Celcuity (CELC) stock appears overvalued, primarily due to its high price-to-book (P/B) ratio of 80.5x, far exceeding industry averages. The mixed valuation score suggests that current expectations already discount substantial …

FuelCell Energy (FCEL) Is Down 12.1% After Siemens Grid Collaboration - Has The Bull Case Changed?

FuelCell Energy (FCEL) recently collaborated with Siemens AG to develop electrical balance-of-plant systems for 100+ MW fuel cell projects, aiming to streamline deployment and costs. While this partnership and recent equity offering strengthen FuelCell Energy's balance sheet and growth potential, investor dilution remains a …

Celcuity (CELC) Receives a Buy from Leerink Partners

Leerink Partners has maintained a Buy rating for Celcuity (CELC) and set a price target of $147.00. This follows Citizens JMP also maintaining a Buy rating with a $177.00 price target. The company reported a quarterly GAAP net loss of $52.84 million for the …

UBS Raises Its FuelCell Energy Stock Forecast With a $27 Stock Price Target

Financial Data by Mer_Studio via Shutterstock FuelCell Energy (FCEL) has been on a wild ride lately. FCEL stock is up more than 250% over the past year, despite trading more than 50% below its 52-week high. Now one major Wall Street firm says the …

Price to sales forward of FuelCell Energy, Inc. – MUN:FEY

This article provides access to the "Price to sales forward" financial metric for FuelCell Energy, Inc. (MUN:FEY) on the Munich Stock Exchange, available through TradingView. It highlights that the market is currently closed and no trades have occurred for this particular metric.

FuelCell Energy, Inc. (NASDAQ:FCEL) Receives Consensus Recommendation of "Hold" from Brokerages

Brokerages have issued a consensus "Hold" rating for FuelCell Energy, Inc. (NASDAQ:FCEL), with an average 1-year price target of $22.83. Recent analyst actions were mixed, including upgrades from Jefferies, UBS, and Canaccord, but also a downgrade from Wall Street Zen. The company's latest earnings …

ETFs Investing in Delcath Systems, Inc. Stocks

This article lists several ETFs that invest in Delcath Systems, Inc. (DCTH) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and total return. The ETFs cover various investment strategies including active and passive management, and focus on small-cap, micro-cap, …

Precision Trading with Celcuity Inc. (CELC) Risk Zones

This article provides a detailed analysis of Celcuity Inc. (NASDAQ: CELC), highlighting weak near-term sentiment despite prevailing positive sentiment. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various risk profiles and holding periods. The report emphasizes …

Is FuelCell Energy (FCEL) Stock Outpacing Its Oils-Energy Peers This Year?

FuelCell Energy (FCEL) is outperforming its Oils-Energy sector peers this year, with a 136.1% gain compared to the sector's 22.8% return. The stock currently holds a Zacks Rank #2 (Buy), and its full-year earnings estimate has increased by 17.1% over the past three months. …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Pomerantz LLP is investigating potential securities fraud claims against Celcuity Inc. (NASDAQ: CELC) on behalf of investors. The investigation follows a significant drop in Celcuity's stock price after the company announced U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk, with …

FuelCell Energy (FCEL) Could Be 21% Undervalued As Siemens And Fit Energy Deals Lift Views

FuelCell Energy (FCEL) is drawing attention after new collaborations with Siemens and Fit Energy, along with analyst upgrades, position it as potentially 21% undervalued despite recent share price volatility. The company's fair value is estimated at $22 against a current trading price of $17.26, …

MLCO Maintained by JP Morgan -- Price Target Lowered to $5.70

JP Morgan maintained a Neutral rating for Melco Resorts and Entertainment (MLCO) but lowered its price target to $5.70 from $6.00, reflecting a cautious outlook due to challenging market conditions in the gaming and hospitality sector. Despite the lowered target, GuruFocus assesses MLCO as …

Four Delcath Employees Receive Stock Awards Tied to Vesting Dates

Delcath Systems, Inc. (Nasdaq: DCTH) announced that it granted 17,000 Restricted Stock Units (RSUs) to four new employees who started in May or June 2026. These equity awards, approved by the Company's Compensation Committee, are designed as material inducements and will vest over three …

Goldman Sachs Maintains Melco Resorts and Entertainment(MLCO.US) With Buy Rating, Cuts Target Price to $8

Goldman Sachs has reiterated its Buy rating on Melco Resorts and Entertainment (MLCO.US) but has adjusted its target price downwards to $8. This indicates a continued positive outlook on the company despite a moderated price expectation.

Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations

Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, signaling a potential multi-billion dollar market opportunity. The drug, a first-in-class pan-PI3K/mTOR inhibitor, demonstrated superior efficacy and a favorable safety profile compared to existing treatments. Despite a significant stock rally leading …

Nelcast (NSE:NELCAST) Could Be A Buy For Its Upcoming Dividend

Celcuity wins FDA approval for REVTORPYK; plans late Q3 commercial launch

Celcuity has received FDA approval for REVTORPYK (gedatolisib) to treat HR+/HER2- metastatic breast cancer without a PIK3CA mutation. The company plans a commercial launch in late Q3 2026, following a Phase 3 trial showing significant reduction in disease progression risk. Celcuity also intends to …

Celcuity’s Revtorpyk wins FDA nod in breast cancer

Celcuity Inc. received FDA approval for Revtorpyk (gedatolisib) for a subset of breast cancer patients, marking the company's first commercial product and a new treatment option. Despite this positive news, investor excitement was dampened by an unanticipated launch delay, causing Celcuity's shares (NASDAQ:CELC) to …

Celcuity gains FDA approval for closely watched breast cancer drug

Celcuity received FDA approval for its breast cancer drug, Revtorpyk, for use in specific combinations for advanced ER-positive, HER2-negative breast cancer patients without a PIK3CA mutation. Despite the approval, Celcuity's shares fell by nearly 20% due to a delayed launch timeline and unexpected discontinuation …

Melco Resorts & Entertainment Limited $MLCO is ARGA Investment Management LP's 10th Largest Position

ARGA Investment Management LP significantly reduced its stake in Melco Resorts & Entertainment (MLCO) by 36.5% during the first quarter, yet MLCO remains its 10th largest holding, constituting 2.7% of its portfolio. Other institutional investors have shown mixed activity, while hedge funds and institutions …

Melco Resorts & Entertainment Limited Stock 12‑Month Price Target Raised to $8.44, Implies 60% Upside

Analysts have raised the average 12-month price target for Melco Resorts & Entertainment Limited (MLCO) stock to $8.44, up from $8.26, indicating a potential 60% upside from its July 9 closing price. The consensus rating among 11 analysts remains "Buy," with 9 Buys and …

Steelcast Ltd FY26 Profit Up 20.3% To ₹86.86 Cr, Declares 171% Dividend

DCTH Forecast — Price Target — Prediction for 2027

NELCO Stock Prediction 2026: Analyst Forecast and Analysis

NELCO Share Analyst Review 2026: Price Target and Outlook

It Might Not Be A Great Idea To Buy Celcomdigi Berhad (KLSE:CDB) For Its Next Dividend

Las opciones de FuelCell Energy anticipan un movimiento del 17%

Steelcast Q4 Net Profit Falls 13.4% to ₹23.2 Crore as Revenue Contracts to ₹112 Crore

Steelcast FY26 net profit rises 20.3% to ₹86.86 crore

Steelcast Ltd schedules Q4FY26 earnings call on June 1

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems Q1 Earnings Call Highlights

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance

Celcuity LLC stock reaches all-time high at 128.29 USD